*June 2021*
Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and set the stage for further research aimed at generating better tolerated, more effective, and optimally sequenced treatments.
Nicholas C. Rohs, MD, an assistant professor of medicine, hematology, and medical oncology at the Icahn School of Medicine of Mount Sinai in New York, New York, moderated a discussion on advances with targeted therapies in NSCLC, highlighting the latest and most pivotal data in the thoracic space and how the data apply to clinical practice. This discussion was part of a recent edition of Thoracic Night Live, a video program in lung cancer from OncLive®.
Rohs was joined by Isabel Preeshagul, DO, MBS, an assistant professor and thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, and Joshua K. Sabari, MD, an assistant professor and thoracic medical oncologist in the Department of Medicine at the Grossman School of Medicine at NYU Langone Health’s Perlmutter Cancer Center, both based in New York, New York.
Read more about the following:
- HER2-Directed Advances
- Updates in EGFR+ NSCLC
- What’s New With KRAS G12C?
- Marked Progress With MET
